TrialThe New England journal of medicine2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Neil D Gross et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
179 papers cite itlatest 60 shown
this paperpooled ittrialcites it